Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Diabetes and Vascular Disease Research

Volumn 9, Issue 4, 2012, Pages 245-255

  Schnell, Oliver ^a   Erbach, Michael ^b   Hummel, Michael ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Sciarc Institut   (Germany)

Author keywords

aspirin; cancer; cardiovascular disease; Diabetes; prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HEMOGLOBIN A1C; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN F1 ALPHA; THROMBOXANE A2; THROMBOXANE B2;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTICOAGULATION; AORTA DISEASE; AORTA DISSECTION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MESENTERIC ARTERY OCCLUSION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; TURNOVER TIME; UNSTABLE ANGINA PECTORIS; VASOCONSTRICTION;

ANIMALS; ANTICARCINOGENIC AGENTS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84866693885     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441486     Document Type: Review

References (105)

1. Schnell O, Standl E. Diabetes and cardiovascular disease. Current status of trials. Clin Res Cardiol. 2010 ; 5: 27-34
2. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 ; 375: 2215-2222
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234
4. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 ; 22: 233-240
5. Dale AC, Midthjell K, Nilsen TI, et al. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. Eur Heart J. 2009 ; 30: 1372-1377
6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359: 1577-1589
7. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006 ; 152: 27-38
8. Otter W, Kleybrink S, Doering W, et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med. 2004 ; 21: 183-187
9. Anselmino M, Ohrvik J, Malmberg K, et al. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008 ; 29: 177-184
10. Schnell O, Schafer O, Kleybrink S, et al. Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry. Diabetes Care. 2004 ; 27: 455-460
11. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010 ; 7: 260-273
12. Dullaart RP, de Vries R, Sluiter WJ, et al. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2009 ; 70: 221-226
13. Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg. 2011 ; 54: 819-831
14. Nicolucci A, Standl E. Antiplatelet therapy for every diabetic person?. Diabetes Care. 2011 ; 34: S150 - S154
15. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005 ; 97: 1679-1687
16. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 ; 364: 829-841
17. Zhou XH, Qiao Q, Zethelius B, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010 ; 53: 1867-1876
18. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 ; 72: 3073-3076
19. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 ; 353: 2373-2383
20. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 ; 69: 1366-1372
21. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000 ; 102: 840-845
22. Bode-Boger SM, Boger RH, Schubert M, et al. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol. 1998 ; 54: 707-714
23. Ciabattoni G, Boss AH, Daffonchio L, et al. Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine. Adv Prostaglandin Thromboxane Leukot Res. 1987 ; 17B: 598-602
24. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 ; 311: 1206-1211
25. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011 ; 32: 2922-2932
26. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007 ; 109: 2285-2292
27. Kyrle PA, Westwick J, Scully MF, et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man-effect of low-dose aspirin. Thromb Haemost. 1987 ; 57: 62-66
28. Undas A, Undas R, Musial J, et al. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis. 2000 ; 11: 231-234
29. Undas A, Brummel K, Musial J, et al. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001 ; 98: 2423-2431
30. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995 ; 310: 827-830
31. Dammann HG. Gastroduodenal tolerabilty profile of low-dose enteric-coated ASA. Gastroenterol Int. 1998 ; 11: 205-216
32. Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment Pharmacol Ther. 1999 ; 13: 187-193
33. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003 ; 1: 1710-1713
34. Sanderson S, Emery J, Baglin T, et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005 ; 142: 370-380
35. Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006 ; 95: 652-658
36. Lordkipanidze M. Why an aspirin a day no longer keeps the doctor away. Thromb Haemost. 2011 ; 105: 209-210
37. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000 ; 101: 1206-1218
38. ZaccardiFPitoccoDRoccaB. Determinants of the variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes. In: 47th annual meeting of EASD, Lisbon, 2011, presentation abstract no. 72, http://www.easd.org. 2011.
39. Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost. 1995 ; 21: 152-160
40. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009 ; 101: 151-156
41. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004 ; 113: 101-113
42. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation. 2006 ; 113: e728-732
43. Mylotte D, Kavanagh GF, Peace AJ, et al. Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets. 2011 ;:
44. Spectre G, Arnetz L, Ostenson CG, et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011 ; 106: 491-499
45. Lordkipanidze M, Pharand C, Schampaert E, et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol. 2010 ; 150: 39-44
46. Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010 ; 115: 1054-1061
47. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2011 ; 9: 185-191
48. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011 ; 4: 180-187
49. Vivas D, Bernardo E, Garcia-Rubira JC, et al. Can resistance to aspirin be reversed after an additional dose?. J Thromb Thrombolysis. 2011 ; 32: 356-361
50. RoccaBSantilliFPitoccoD. Variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes. In: AHA 2010 scientific sessions, Chicago, 2010, abstract 12223, http://circ.ahajournals.org/cgi/content/meeting-abstract/122/ 21-MeetingAbstracts/A12233.
51. Schwartz KA, Schwartz DE, Barber K, et al. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008 ; 6: 46
52. Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J. 2009 ; 157: 889-893
53. Dalen JE. Aspirin resistance: is it real? Is it clinically significant?. Am J Med. 2007 ; 120: 1-4
54. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005 ; 6: 2027-2045
55. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005 ; 95: 973-975
56. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J. 2004 ; 147: 293-300
57. Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study. Diabetes Care. 2010 ; 33: 317-321
58. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989 ; 321: 129-135
59. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992 ; 268: 1292-1300
60. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003 ; 26: 3264-3272
61. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 ; 352: 1293-1304
62. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 ; 337: a1840
63. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 ; 300: 2134-2141
64. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 ; 351: 1755-1762
65. Hebert PR, Schneider WR, Hennekens CH. Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment. J Gen Intern Med. 2009 ; 24: 1248-1250
66. Manson JE, Grobbee DE, Stampfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990 ; 89: 772-776
67. Younis N, Williams S, Soran H. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes Obes Metab. 2009 ; 11: 997-1000
68. Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011 ; 34: 280-285
69. Elwood P. POPADAD trial. Don't stop taking aspirin. BMJ. 2008 ; 337: a2581
70. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86
71. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009 ; 339: b4531
72. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010 ; 87: 211-218
73. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373: 1849-1860
74. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009 ; 32: 2300-2306
75. Butalia S, Leung AA, Ghali WA, et al. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011 ; 10: 25
76. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010 ; 33: 1395-1402
77. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 ; 56: 2382-2391
78. The Medical Research Council's General Practice Research Framework. Lancet. 1998 ; 351: 233-241
79. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988 ; 296: 313-316
80. Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008 ; 156: 1002 e1001-1002 e1007
81. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 ; 150: 405-410
82. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 ; 150: 396-404
83. UKPDS Risk Engine, http://www.dtu.ox.ac.uk/riskengine/.
84. ARIC CHD Risk Calculator, http://www.aricnews.net/riskcalc/html/RC1.html.
85. ADA Risk Assessment Tool, Diabetes PHD, https://www.diabetesarchive.net/ phd/profile/.
86. Antiplatelet Trialists' Collaboration. BMJ. 1994 ; 308: 235-246
87. Triplitt C, Alvarez CA. Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectrum. 2008 ; 21: 177-189
88. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 2004 ; 1: S72-73
89. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007 ; 28: 2375-2414
90. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004 ; 25: 166-181
91. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 ; 28: 88-136
92. International Diabetes Federation: Global guideline for type 2 diabetes, 2005, http://www.idf.org/guidelines/type-2-diabetes.
93. Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk of colon cancer: implications for prevention. Cancer Causes Control. 1997 ; 8: 649-667
94. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995 ; 122: 327-334
95. Giovannucci E, Colditz GA, Stampfer MJ, et al. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control. 1996 ; 7: 253-263
96. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010 ; 33: 1674-1685
97. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?. Cancer Epidemiol Biomarkers Prev. 1994 ; 3: 687-695
98. Lund Nilsen TI, Vatten LJ. Colorectal cancer associated with BMI, physical activity, diabetes, and blood glucose. IARC Sci Publ. 2002 ; 156: 257-258
99. Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006 ; 107: 28-36
100. Bjork J, Nilsson J, Hultcrantz R, et al. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol. 1993 ; 28: 879-884
101. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 ; 376: 1741-1750
102. Meade TW, Wilkes HC, Stirling Y, et al. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J. 1988 ; 9: 836-843
103. The SALT Collaborative Group. Lancet. 1991 ; 338: 1345-1349
104. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991 ; 54: 1044-1054
105. The Dutch TIA Trial Study Group. N Engl J Med. 1991 ; 325: 1261-1266